Skip to main content

Cost-efficient European adaptations of global health economic models

Experience with model adaptations in Austria, Belgium, France, Germany, Italy, Norway, Netherlands, Spain, Sweden, the UK

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Post-experiment transitional period for innovative technologies is launched in France

On July 07, 2023, the Ministry of Health and Prevention announced the implementation of the transitional period for innovative technologies following the experiment under Article 51 of the Social Security Financing Act. The post-experiment transitional phase was enabled by the Social Security Financing Act (LFSS) 2022, and can be seen as the next phase of the Article 51 experimentation phase. 

The post-experiment transitional phase was introduced following the favorable opinion of the Strategic Council for Health Innovation for entry into common law and makes it possible to maintain the experiment in operational conditions until common law is operational and can take over.

The first transitional period following the experiment under Article 51 was provided for health innovation "Management of gestational diabetes with telemonitoring," which includes telemonitoring of patients with the myDiabby Healthcare solution, with a total maximum amount of €894,000 for eight months.

See the details in French here 

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.